Table 1 Baseline demographics and disease characteristics of pooled clinical trial patient population
Characteristic | PsO studies | PsA studies | AS studies |
|---|---|---|---|
Any secukinumab N = 5181 | Any secukinumab N = 1380 | Any secukinumab N = 794 | |
Age (years), mean (SD) | 45.7 (13.3) | 48.8 (12.0) | 42.4 (12.3) |
Female, n (%) | 1743 (33.6) | 742 (53.8) | 265 (33.4) |
Caucasian, n (%) | 4236 (81.8) | 1212 (87.8) | 612 (77.1) |
BMI, mean (SD) | 29.1 (6.6) | 29.8 (6.3) | 27.2 (5.5) |
Relevant medical history or current medical condition, n (%) | |||
 Hypertension | 1089 (21.0) | 551 (39.9) | 176 (22.2) |
 Hyperlipidemia | 667 (12.9) | 318 (23.0) | 65 (8.2) |
 Diabetes mellitus | 341 (6.6) | 171 (12.4) | 22 (2.8) |
 IBD | 0 (0) | 4 (0.3) | 17 (2.1) |
 Crohn’s disease | 5 (0.1) | 2 (0.1) | 5 (0.6) |
 Ulcerative colitis | 10 (0.2) | 2 (0.1) | 3 (0.4) |
 Uveitis | 0 (0) | 8 (0.6) | 135 (17.0) |
 Current smoker | 1585 (30.6) | 262 (19.0) | 234 (29.5) |
 Anti-TNF inadequate responder | 784 (15.1) | 435 (31.5) | 227 (28.6) |